Replimune Group, Inc. — Form 8-K Summary
Reporting date: October 6, 2022, the closing date of the financing. The filing was signed October 7, 2022. Replimune is a Delaware biotechnology company; the filing concerns a new secured term loan facility rather than periodic operating results.
Material Financing and Key Terms
- Replimune and certain subsidiaries entered into a Loan and Security Agreement with Hercules Capital, Inc. as administrative and collateral agent and lender, together with other potential lenders.
- The facility provides for up to $200.0 million of term loans in multiple tranches, subject to conditions and milestone requirements.
- An initial $30.0 million advance was funded on October 6, 2022. An additional $30.0 million may be drawn by September 30, 2023.
- Up to $115.0 million of additional advances may become available upon achievement of specified performance milestones. Up to another $25.0 million may be available in as many as two advances, subject to lender investment committee approval.
- Proceeds may be used for working capital and general corporate purposes.
- The facility matures on October 1, 2027.
- Cash interest is payable at a floating annual rate equal to the greater of 7.25% and the Prime Rate, capped at 7.25%, plus 1.75%. The filing also describes 1.50% PIK interest, which is added to principal on each interest payment date.
- Interest is payable monthly after each advance. Principal amortization is generally deferred during a 48-month interest-only period, which may be extended to 54 months or potentially through maturity if specified milestones are achieved.
Financial Metrics and Liquidity
The filing does not provide revenue, net income or loss, operating cash flow, cash balance, margin, or other periodic operating metrics. It reports the initial $30.0 million borrowing and establishes additional borrowing capacity, but does not state the company’s post-closing liquidity or total debt balance.
Material Changes and Covenants
- The transaction creates a new secured financial obligation and represents a material change to Replimune’s capital structure and liquidity resources.
- Beginning January 1, 2024, the borrowers must maintain specified levels of unrestricted cash in accounts subject to the agent’s control agreement.
- Beginning on the later of July 1, 2024, or the date aggregate outstanding principal reaches at least $100.0 million, the borrowers must satisfy one of several conditions: achieve minimum trailing three-month net product revenue, maintain market capitalization above $1.2 billion plus unrestricted cash equal to at least 50% of outstanding facility obligations, or maintain unrestricted cash equal to at least 85% of outstanding facility obligations.
- The agreement contains customary facility fees, representations, warranties, affirmative and negative covenants, and events of default.
Outlook, Risks and Unusual Items
Management did not provide operating guidance in the filing. The facility expands potential funding for corporate and working-capital needs, but future availability is conditional on performance milestones and, for certain tranches, lender approval. Cash interest, PIK interest, future principal repayment, floating-rate exposure, cash-maintenance requirements, and financial covenants could constrain liquidity. Failure to satisfy covenants or other obligations could result in an event of default.
The company stated that it planned to file the complete Loan Agreement as an exhibit to its Form 10-Q for the quarter ended September 30, 2022 and intended to seek confidential treatment. The summary terms in this 8-K are qualified by the full agreement.
Facts Investors Should Verify
- Whether the full Loan Agreement was subsequently filed and whether confidential treatment affected disclosure of material terms.
- The company’s cash balance, total debt, borrowing base, facility fees, and any transaction-related financing costs.
- Achievement status of the milestones required for the additional $115.0 million tranche and eligibility for the potential $25.0 million tranche.
- The exact unrestricted-cash thresholds and any amendments, waivers, defaults, or covenant compliance disclosures after January 1, 2024.
- The applicable cash interest rate over time and the cumulative effect of 1.50% PIK interest on outstanding principal.